| |
Lipohypertrophy |
Lipoatrophy |
Lipodystrophy |
| Antiretroviral treatment (ART) |
1.33 (1.15–1.52)* |
1.33 (1.18–1.50)* |
1.22 (1.13–1.32)* |
| ART+gender |
1.34 (1.16–1.54)* |
1.33 (1.18–1.50)* |
1.22 (1.13–1.32)* |
| ART+age (years) |
1.31 (1.14–1.51)* |
1.34 (1.18 – 1.52)* |
1.22 (1.12–1.32)* |
| ART+skin color |
1.34 (1.16 – 1.54)* |
1.34 (1.18–1.51)* |
1.23 (1.14–1.33)* |
| ART, complete model# |
1.49 (1.30 – 1.70)* |
1.30 (1.15–1.47)* |
1.23 (1.13–1.33)* |
| Protease inhibitors (PI) |
1.16 (1.03–1.31)** |
1.22 (1.10–1.36)* |
1.14 (1.07–1.22)* |
| PI+gender |
1.13 (1.00–1.27)** |
1.23 (1.11–1.36)* |
1.14 (1.07–1.22)* |
| PI+age (years) |
1.15 (1.02–1.30)△ |
1.22 (1.10–1.36)* |
1.14 (1.07–1.21)* |
| PI+skin color |
1.17 (1.04–1.32)** |
1.24 (1.12–1.38)* |
1.15 (1.08–1.23)* |
| PI, complete model# |
1.23 (1.10–1.38)* |
1.20 (1.08–1.32)* |
1.15 (1.07–1.22)* |
#Adjusted for gender, skin color, smoking status, BMI and CD4
*P value<0.001; **P value 0.01 ≤ P ≤ 0.05; △P value=0.19 |
|
